The clinical need for clustered AChR cell-based assay testing of seronegative MG

Competing Interest Statement

Dr. Gianvito Masi, Dr. Yingkai Li, Tabitha Karats, Minh C. Pham and Seneca R. Oxendine report no disclosures. Dr. Nowak has received research support from the National Institutes of Health (NIH), Genentech, Inc, Alexion Pharmaceuticals, Inc, argenx, Annexon Biosciences, Inc, Ra Pharmaceuticals, Inc (now UCB S.A.), the Myasthenia Gravis Foundation of America (MGFA), Momenta Pharmaceuticals, Inc, Immunovant, Inc, Grifols, S.A., and Viela Bio, Inc (part of Horizon Therapeutics plc). He has served as consultant and advisor for Alexion Pharmaceuticals, Inc, argenx, Cabaletta Bio, Inc, CSL Behring, Grifols, S.A., Ra Pharmaceuticals, Inc (now UCB S.A.), Immunovant, Inc, Momenta Pharmaceuticals, Inc, and Viela Bio, Inc (part of Horizon Therapeutics plc). Dr. Jeffrey T. Guptill has received consulting fees/honoraria from Immunovant, Alexion, Apellis, Momenta, Ra Pharma, Cabaletta, Regeneron, argenx, Janssen, UCB, and Toleranzia. JTG receives industry grant support from UCB pharma for a fellowship training grant; is a site investigator for Alexion, Janssen, UCB Pharma, argenx, Takeda and grant/research support from: NIH (NIAID, NINDS, NIMH), MGFA, CDC. Full disclosure statement available at: https://dcri.org/about-us/conflict-of-interest. Dr. Kevin C. O'Connor receives research support from Alexion, now part of AstraZeneca, and Viela Bio, now part of Horizon Therapeutics. KCO is a consultant and equity shareholder of Cabaletta Bio and is the recipient of a sponsored research subaward from Cabaletta Bio. KCO has served as consultant/advisor for Alexion Pharmaceuticals, now part of AstraZeneca, and for Roche, and he has received speaking fees from Alexion, Roche, Genentech, and Viela Bio, now part of Horizon Therapeutics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Funding Statement

This work was supported by the Targeted Research Project for Seronegative Myasthenia Gravis award from the Myasthenia Gravis Foundation of America (MGFA). Additional support to Dr. Kevin O'Connor was provided by the National Institute of Allergy and Infectious Diseases of the NIH under award numbers R01-AI114780 and R21-AI164590.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by Yale and Duke Universities' Institutional Review Board.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes